purchased from Bachem. Erenumab, a CGRP receptor monoclonal antibody
(Amgen; lot 1093104), fremanezumab, a CGRP ligand monoclonal antibody
(Teva Pharmaceuticals; lot E15204A001) and isotype control IgG2
antibody (prepared in-house) were used. For flow cytometry, the
following antibodies were used: Anti-human IgG Fc APC (Biolegend),
anti-human IgG Fc BV421 Biolegend), anti-HA.11 PE (Biolegend), Human
c-Myc Alexa Fluor 647-conjugated Antibody (R&D systems) and
anti-myc-FITC (Sigma). For imaging experiments, the following
antibodies were used: Early endosomal marker (early endosomal antigen
1 (EEA1), Abcam), lysosomal marker (lysosomal-associated membrane
protein 1 (LAMP1), Abcam), late endosome marker (Ras-related protein
Rab11, Cell Signaling), goat anti-human 594 and goat anti-rabbit Alexa
Fluor 647 (Invitrogen). The small molecule CGRP receptor antagonist
telcagepant (MedChemExpress) was used.